Department of Gastrointestinal Surgery, Jichi Medical University, Yakushiji 3311-1, Shimotsuke, Tochigi, 329-0498, Japan.
Department of Clinical Oncology, Jichi Medical University, Shimotsuke, Japan.
BMC Cancer. 2020 May 12;20(1):411. doi: 10.1186/s12885-020-06893-3.
Anti-tumor effects of radiation therapy (RT) largely depend on host immune function. Adenosine with its strong immunosuppressive properties is an important immune checkpoint molecule.
We examined how intra-tumoral adenosine levels modify anti-tumor effects of RT in a murine model using an anti-CD73 antibody which blocks the rate-limiting enzyme to produce extracellular adenosine. We also evaluated CD73 expression in irradiated human rectal cancer tissue.
LuM-1, a highly metastatic murine colon cancer, expresses CD73 with significantly enhanced expression after RT. Subcutaneous (sc) transfer of LuM-1 in Balb/c mice developed macroscopic sc tumors and microscopic pulmonary metastases within 2 weeks. Adenosine levels in the sc tumor were increased after RT. Selective RT (4Gyx3) suppressed the growth of the irradiated sc tumor, but did not affect the growth of lung metastases which were shielded from RT. Intraperitoneal administration of anti-CD73 antibody (200 μg × 6) alone did not produce antitumor effects. However, when combined with RT in the same protocol, anti-CD73 antibody further delayed the growth of sc tumors and suppressed the development of lung metastases presumably through abscopal effects. Splenocytes derived from RT+ CD73 antibody treated mice showed enhanced IFN-γ production and cytotoxicity against LuM-1 compared to controls. Immunohistochemical studies of irradiated human rectal cancer showed that high expression of CD73 in remnant tumor cells and/or stroma is significantly associated with worse outcome.
These results suggest that adenosine plays an important role in the anti-tumor effects mediated by RT and that CD73/adenosine axis blockade may enhance the anti-tumor effect of RT, and improve the outcomes of patients with locally advanced rectal cancer.
放射治疗(RT)的抗肿瘤作用在很大程度上取决于宿主的免疫功能。腺苷具有很强的免疫抑制特性,是一种重要的免疫检查点分子。
我们使用一种抗 CD73 抗体来研究肿瘤内腺苷水平如何改变 RT 在小鼠模型中的抗肿瘤作用,该抗体可阻断产生细胞外腺苷的限速酶。我们还评估了放射治疗后人类直肠癌细胞中 CD73 的表达。
LuM-1 是一种高度转移性的小鼠结肠癌细胞,在 RT 后表达 CD73 的表达显著增强。将 LuM-1 皮下(sc)转移到 Balb/c 小鼠中,在 2 周内形成了肉眼可见的 sc 肿瘤和显微镜下的肺转移。RT 后 sc 肿瘤中的腺苷水平增加。选择性 RT(4Gyx3)抑制了照射 sc 肿瘤的生长,但不影响免受 RT 影响的肺转移的生长。单独腹腔内给予抗 CD73 抗体(200μg×6)没有产生抗肿瘤作用。然而,当与相同方案中的 RT 联合使用时,抗 CD73 抗体进一步延迟了 sc 肿瘤的生长,并抑制了肺转移的发展,推测是通过远隔效应。与对照组相比,来自 RT+CD73 抗体治疗小鼠的脾细胞显示出增强的 IFN-γ 产生和对 LuM-1 的细胞毒性。对放射治疗后的人类直肠癌的免疫组织化学研究表明,残留肿瘤细胞和/或基质中 CD73 的高表达与预后较差显著相关。
这些结果表明,腺苷在 RT 介导的抗肿瘤作用中起着重要作用,CD73/腺苷轴阻断可能增强 RT 的抗肿瘤作用,并改善局部晚期直肠癌患者的预后。